Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07549958 · ClinicalTrials.gov registry record · Phase 1
PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)
A Phase 1 study, sponsored by University of California, Irvine.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT07549958 is a Phase 1 study that is actively recruiting participants, run by University of California, Irvine. The registered enrollment target is 18 participants.
The verdict
NCT07549958, a Phase 1 study, is actively recruiting participants, sponsored by University of California, Irvine.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disease.
Interventions
- DRUG Pitavastatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-03-24 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07549958
The ClinicalTrials.gov registry entry for NCT07549958 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pitavastatin is the first listed.
NCT07549958 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07549958 about?
NCT07549958 is a clinical study titled "PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC)". This is a phase 1, open-label clinical trial determining the recommended Phase 2 dose of Gemcitabine with Nab-paclitazel with or without Pitavastatin in subjects with unresectable pancreatic adenocarcinoma (uPDAC). These are subjects who are already receiving Gemcitabine for treatment of their disea...
What is the current status of trial NCT07549958?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-03-24. Estimated completion is 2028-03-31.
What interventions are being tested in trial NCT07549958?
The interventions under investigation include: Pitavastatin (DRUG).
Who is sponsoring clinical trial NCT07549958?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.